论文信息 - FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes. - 字舞流文

FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.

J. Roukema | M. C. Hagemeijer | A. Vonk | E. de Poel | E. Kruisselbrink | R. van der Meer | G. Berkers | P. van Mourik | J. E. Brunsveld | S. Spelier | S. Suen | K. M. de Winter – de Groot | A. R. Blaazer | S. Jans | H. van Panhuis | A. Blaazer | C. van der Ent | S. Heida-Michel | J.E. Muijlwijk-Koezen | G. Ithakisiou | G. Koppelman | J. M. Beekman | H. Oppelaar | M. Bakker | E. Dompeling | E.J.M. Weersink | J. Beekman | G. N. Ithakisiou